<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919840</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ROT-2010-15</org_study_id>
    <nct_id>NCT01919840</nct_id>
  </id_info>
  <brief_title>Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol</brief_title>
  <acronym>ROTEM-2010</acronym>
  <official_title>Indicación de transfusión de Hemoderivados en el Postoperatorio de cirugía Cardiaca Tras la implantación de un Sistema de monitorización de la coagulación a la Cabecera Del Paciente: Tromboelastometría Versus Protocolo Habitual de transfusión</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective:

      Determine whether by introducing thromboelastograph, the investigators reduced the number of
      packed red cells received by each patient (median) compared to the usual protocol, in which
      the indication for transfusion is based on laboratory tests: Prothrombin time, time activated
      partial thromboplastin time, thrombin, reptilase, fibrinogen and platelet contage.

      Design:

      Prospective randomized controlled trial and single blinded.

      Disease or disorder under study:

      Study of coagulopathy in patients undergoing cardiac surgery with cardiopulmonary bypass
      (CPB).

      Primary endpoint:

      median transfusion of packed red blood cells per patient. Study population Male and female
      patients over 18 years undergoing cardiac surgery with cardiopulmonary bypass to bleed
      excessively.

      Duration of treatment:

      The coagulation monitoring methods tested are made from protamine administration to CEC
      output if a) the patient bleeds diffusely, or b) from arrival in the unit if not satisfied
      critics a) bleed excessively drains and until the patient stops bleeding (debit drains &lt;a
      150ml / h).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment after the expected time to finish the study
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median transfusion of packed red cells per patient</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate transfusion of platelets pool and plasma pool</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hemostatic Disorders</condition>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>• conventional protocol, volume replacement with massive bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ROTEM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Protocol according to the different tests to be performed with thromboelastography</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Group ROTEM</intervention_name>
    <description>10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.
If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected.</description>
    <arm_group_label>Group ROTEM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group C</intervention_name>
    <description>10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.
If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients

          -  over 18 years

          -  undergoing cardiac surgery

          -  with cardiopulmonary bypass

          -  bleed excessively

        As it is not possible to predict in advance who will bleed, informed consent will be
        required for all patients over 18 who are to undergo cardiac surgery with CPB.

        Will be randomized to either group

          1. Those patients with diffuse bleeding after protamine administration. and / or

          2. They bleed excessively after surgery. Are excessive bleeding criteria: the debit ≥
             300ml drains in the first hour; ≥ 250ml in the second hour or ≥ 150ml at any later
             time. Consider that the patient is bleeding excessively when the drains debit is
             &lt;150ml.

        Exclusion Criteria:

          -  Patients &lt;18 years

          -  Extracorporeal circulation surgery

          -  Surgery with Mini extracorporeal circulation (MECC)

          -  Refuse to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Paniagua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemostatic disorders</keyword>
  <keyword>ardiac surgery</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

